SCOPUS 정보 검색 플랫폼

Clinical Therapeutics

Volumn 30, Issue SUPPL. 2, 2008, Pages

Implications of early renal changes in fabry disease

(2) Mauer, Michael a Najafian, Behzad a

a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE BETA; GLOBOTRIAOSYLCERAMIDE;

ARTICLE; DIABETIC NEPHROPATHY; DISEASE COURSE; ENDOTHELIUM CELL; ENZYME REPLACEMENT; FABRY NEPHROPATHY; HUMAN; KIDNEY FUNCTION; PATHOGENESIS; PROTEINURIA; SYMPTOMATOLOGY;

ADULT; AGE OF ONSET; CHILD; ENDPOINT DETERMINATION; FABRY DISEASE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; PROTEINURIA; TRIHEXOSYLCERAMIDES;

EID: 41449110025 PISSN: 01492918 EISSN: 1879114X Source Type: Journal
DOI: 10.1016/S0149-2918(08)80034-3 Document Type: Article

Times cited : (2)

References (8)

1
- 0035153448
- Natural history of Fabry disease in males: Preliminary observations
- Schiffmann R. Natural history of Fabry disease in males: Preliminary observations. J Inherit Metab Dis 24 Suppl 2 (2001) 15-27
- (2001) J Inherit Metab Dis , vol.24 , Issue.SUPPL. 2 , pp. 15-27
- Schiffmann, R.¹

2
- 10644231988
- Fabry disease: Overall effects of agalsidase alfa treatment
- Beck M., Ricci R., Widmer U., et al. Fabry disease: Overall effects of agalsidase alfa treatment. Eur J Clin Invest 34 (2004) 838-844
- (2004) Eur J Clin Invest , vol.34 , pp. 838-844
- Beck, M.¹ Ricci, R.² Widmer, U.³

3
- 31544456336
- Long-term therapy with agalsidase alfa for Fabry disease: Safety and effects on renal function in a home infusion setting
- Schiffmann R., Ries M., Timmons M., et al. Long-term therapy with agalsidase alfa for Fabry disease: Safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21 (2006) 345-354
- (2006) Nephrol Dial Transplant , vol.21 , pp. 345-354
- Schiffmann, R.¹ Ries, M.² Timmons, M.³

4
- 33846908304
- for the Fabry Disease Clinical Trial Study Group
- Banikazemi M., Bultas J., Waldek S., et al. for the Fabry Disease Clinical Trial Study Group. Agalsidase-beta therapy for advanced Fabry disease: A randomized trial. Ann Intern Med 146 (2007) 77-86
- (2007) Agalsidase-beta therapy for advanced Fabry disease: A randomized trial. Ann Intern Med , vol.146 , pp. 77-86
- Banikazemi, M.¹ Bultas, J.² Waldek, S.³

5
- 34248190164
- long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease
- Germain D., Waldek S., Banikazemi M., et al. long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18 (2007) 1547-1557
- (2007) J Am Soc Nephrol , vol.18 , pp. 1547-1557
- Germain, D.¹ Waldek, S.² Banikazemi, M.³

6
- 33645528253
- Clinical benefit of enzyme replacement therapy in Fabry disease
- Breunig F., Weidemann F., Strotmann J., et al. Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 69 (2006) 1216-1221
- (2006) Kidney Int , vol.69 , pp. 1216-1221
- Breunig, F.¹ Weidemann, F.² Strotmann, J.³

7
- 0017872842
- Early renal changes in hemizygous and heterozygous patients with Fabry′s disease
- Gubler M., Lenoir G., Grünfeld J., et al. Early renal changes in hemizygous and heterozygous patients with Fabry′s disease. Kidney Int 13 (1978) 223-235
- (1978) Kidney Int , vol.13 , pp. 223-235
- Gubler, M.¹ Lenoir, G.² Grünfeld, J.³

8
- 21344454447
- for the International Diabetic Nephropathy Study Group
- Steinke J., Sinaiko A., Kramer M., et al. for the International Diabetic Nephropathy Study Group. The early natural history of nephropathy in type 1 diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 54 (2005) 2164-2171
- (2005) The early natural history of nephropathy in type 1 diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes , vol.54 , pp. 2164-2171
- Steinke, J.¹ Sinaiko, A.² Kramer, M.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.